secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001070081-23-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics reports 2022 revenue of $699M (+30% YoY); reaffirms 2023 guidance of $940M-$1B
--------------------------------------------------------------------------------

- 2022 total revenue $698.8M (+30% YoY); DMD franchise $507M (+20% YoY).
- Translarna net revenue $288.6M; Emflaza $218.3M; Evrysdi royalty $113.5M.
- Net loss $559M for 2022; cash $410.7M at Dec 31, 2022.
- 2023 guidance: total revenue $940M-$1B; DMD franchise $545M-$565M.
- Four key study readouts expected H1 2023: sepiapterin PKU (May), vatiquinone MIT-E and MOVE-FA, PTC518 HD (Q2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/0001070081-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/tmb-20230221x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer